[en] Inflammatory flare-up reactions of some dermatomycoses, particularly those caused by zoophilic fungi, are typical and potentially severe adverse effects following the intake of some oral antifungals. However, this condition has not previously been reported with the most frequently used antifungals in dermatology, namely fluconazole, itraconazole, and terbinafine. In this report, we describe five patients, observed over a 10-year period, who presented with inflammatory exacerbations following oral antifungal therapy for dermatomycoses. We also review the literature on inflammatory reactions exacerbated by oral antifungal agents. Details of the patients' age, sex, occupation, and atopic background; the site of the lesion, its clinical and histologic features, and any systemic signs; the identity of the fungal pathogen; the antifungal agent taken by the patient; the time between drug intake and occurrence of the flare-up; the approach to management; and the outcome were documented for each patient. A PubMed literature search was also conducted, focusing on inflammatory exacerbations induced by griseofulvin, ketoconazole, itraconazole, fluconazole, and terbinafine. The patients were four farmers and one veterinarian (all male). All primary lesions were inflammatory dermatophytoses, including one kerion. Inflammatory exacerbation of the skin lesions started 12-24 hours after the intake of oral antifungals. Mild systemic changes, including slight fever and malaise, occurred in two cases. Itraconazole 400 mg/day was implicated as the causative agent in four cases and terbinafine 250 mg/day in one case. Mycologic cultures grew Trichophyton verrucosum in four cases. Antifungal treatment was discontinued in all patients. Oral and topical corticosteroids were administered to the two patients with systemic changes; the other three patients were treated with topical corticosteroids only. Two days after the onset of corticosteroids, lower doses of itraconazole (100 mg/day) and terbinafine (125 mg/day) were reintroduced. All lesions healed after 4-5 weeks. The PubMed search did not identify any articles that described inflammatory exacerbations of dermatomycoses induced by oral antifungals. Inflammatory flare-up of der-matomycoses is a rare but potentially severe cutaneous complication of oral antifungal use. Occupational contact with animals, inflammatory dermatomycoses, and zoophilic fungi represent common features in these patients. Although evidence-based data are not available, clinical experience shows that, in addition to antifungal therapy, topical and/or systemic corticosteroids are helpful to reduce the inflammatory reactions. The cases described in this article represent the first published report of oral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis in patients taking itraconazole or terbinafine.
Disciplines :
Dermatology
Author, co-author :
Nikkels, Arjen ; Université de Liège - ULiège > Dermatologie
Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996; 52: 209-24
McClellan KJ, Wiseman LR, Markham A. Terbinafine: an update of its use in superficial mycoses. Drugs 1999; 58: 179-202
Grant SM, Clissold SP. Ketoconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-44
Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585-620
Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Exp Opin Pharmacother 2000; 1: 287-304
Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-90
Baran R, Gupta AK, Pierard GE. Pharmacotherapy of onychomycosis. Exp Opin Pharmacother 2005; 6: 609-24
Bork K. Jarisch-Herxheimer reaction and ketoconazole. In: Bork K, editor. Cutaneous side effects of drugs. 1st ed. New York: WB Saunders Company, 1988: 24
Litt JZ. Drug eruption reference manual. 11th ed. New York: Taylor and Francis, 2005
Bryceson AD. Clinical pathology of the Jarisch-Herxheimer reaction. J Infect Dis 1976; 133: 696-704
Melkert PW. Fatal-Jarisch Herxheimer reaction in a case of relapsing fever misdiagnosed as lobar pneumonia. Trop Geogr Med 1987; 39: 92-3
Coxon RE, Fekade D, Knox K, et al. The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever. QJM 1997; 90: 213-21
Kaplanski G, Granel B, Vaz T, et al. Jarisch-Herxheimer reaction complicating the treatment of chronic Q fever endocarditis: elevated TNFalpha and IL-6 serum levels. J Infect 1998; 37: 83-4
Arnez M, Pleterski-Rigler D, Luznik-Bufon T, et al. Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien Klin Wochenschr 2002; 114: 498-504
Genc M, Ledger WJ. Syphilis in pregnancy. Sex Transm Infect 2000; 76: 73-9
Barriere H, Litoux P. Intérêt et justification de la corticotherapie générale dans la teigne suppurative. Ann Dermatol Venereol 1977; 104: 294-7
Nichter LS, Thomas DM, Atkinson J, et al. Scalp infections in black children: think kerion. Plast Reconstr Surg 1987; 80: 717-9
Stephens CJ, Hay RJ, Black MM. Fungal kerion: total scalp involvement due to Microsporum canis infection. Clin Exp Dermatol 1989; 14: 442-4
Munteanu M. Traitements pratiques des mycoses suppuratives de la peau et des mycoses allergiques cutanées dues au Candida. Rev Med Chir Soc Med Nat Iasi 1990; 94: 631-4
Kick G, Korting HC. Debilitating folliculitis barbae candidomycetica in a trumpeter: successful treatment with fluconazole. Mycoses 1998; 41: 339-42
Elewski BE, El Charif M, Copper KD, et al. Reactivity to trichophyton antigen in patients with onychomycosis: effect of terbinafine. J Am Acad Dermatol 2002; 46: 371-5
Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005; 30: 291-5
Hassig A. Intravenous immunoglobulins: pharmacological aspects and therapeutic use. Vox Sang 1986; 51: 10-7
Remick DG, Negussie Y, Fekade D, et al. Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. J Infect Dis 1996; 174: 627-30
Teklu B, Habte-Michael A, Warrell DA, et al. Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever. Lancet 1983; 1: 835-9
Cooper PJ, Fekade D, Remick DG, et al. Recombinant human interleukin-10 fails to alter proinflammatory cytokine production or physiologic changes associated with the Jarisch-Herxheimer reaction. J Infect Dis 2000; 181: 203-9
Griffin GE. Cytokines involved in human septic shock: the model of the Jarisch-Herxheimer reaction. J Antimicrobial Chemotherapy 1998; 41 Suppl. A: 25-9
Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335: 311-5
Aste N, Pau M, Biggio P. Kerion celsi: a clinical epidemiological study. Mycoses 1998; 41: 169-73
Nolting S, Rogalla K. Double-blind comparison of miconazole/ corticosteroid combination versus miconazole in inflammatory dermatomycoses. Int J Dermatol 1995; 34: 125-8